Scott Fung
Overview
Explore the profile of Scott Fung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dongelmans E, Feld J, Boonstra A, Brakenhoff S, Wong D, Yim C, et al.
Aliment Pharmacol Ther
. 2024 Dec;
61(3):570-578.
PMID: 39624922
Background: Severe flares (ALT ≥ 10×ULN) are a well-recognised adverse outcome after nucleos(t)ide analogue (NA) cessation and may lead to liver failure. Thus, identification of patients at risk for these...
2.
Jagarlamudi N, Reyes M, Fung S, Wong F
J Clin Med
. 2024 Apr;
13(7).
PMID: 38610629
Currently, there are insufficient data to recommend the treatment of patients with hepatitis B e antigen (HBeAg)-negative chronic infection who have normal ALT and low HBV DNA, since the prognosis...
3.
Yuen M, Fung S, Ma X, Nguyen T, Hassanein T, Hann H, et al.
JHEP Rep
. 2024 Mar;
6(4):100999.
PMID: 38510983
Background & Aims: The investigational first-generation core inhibitor vebicorvir (VBR) demonstrated safety and antiviral activity over 24 weeks in two phase IIa studies in patients with chronic HBV infection. In...
4.
Janssen H, Lim Y, Kim H, Sowah L, Tseng C, Coffin C, et al.
JHEP Rep
. 2024 Jan;
6(2):100975.
PMID: 38274492
Background & Aims: Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated...
5.
Zewude R, Corbeil A, Fung S, Moulton C, Bogoch I
J Assoc Med Microbiol Infect Dis Can
. 2024 Jan;
8(4):336-342.
PMID: 38250619
Background: Alveolar echinococcus, caused by the tapeworm , mimics hepatic malignancy, and carries a mortality rate exceeding 90% in untreated patients. Methods: Diagnosis of infection is established through clinical, radiographic,...
6.
Farag M, van Campenhout M, Sonneveld M, Fung S, van Erpecum K, Wong D, et al.
J Viral Hepat
. 2024 Jan;
31(4):197-207.
PMID: 38243144
We studied whether 48 weeks of PEG-IFN alfa-2a add-on increases HBsAg-decline and clearance in HBeAg-negative patients on long-term nucleo(s)tide analogue (NA) therapy. In this investigator-initiated, randomized, controlled trial conducted in...
7.
Lim Y, Chan H, Ahn S, Seto W, Ning Q, Agarwal K, et al.
JHEP Rep
. 2023 Sep;
5(10):100847.
PMID: 37771546
Background & Aims: Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir...
8.
Kim S, Wallin J, Ghosheh Y, Zahoor M, Vasquez J, Nkongolo S, et al.
JHEP Rep
. 2023 Aug;
5(9):100817.
PMID: 37600958
Background & Aims: Novel therapies for chronic hepatitis B (CHB), such as RNA interference, target all viral RNAs for degradation, whereas nucleoside analogues are thought to block reverse transcription with...
9.
Chan H, Buti M, Lim Y, Agarwal K, Marcellin P, Brunetto M, et al.
Am J Gastroenterol
. 2023 Aug;
119(3):486-496.
PMID: 37561058
Introduction: The results from 2 phase 3 studies, through 2 years, in chronic hepatitis B infection showed tenofovir alafenamide (TAF) had similar efficacy to tenofovir disoproxil fumarate (TDF) with superior...
10.
Nkongolo S, Mahamed D, Kuipery A, Sanchez Vasquez J, Kim S, Mehrotra A, et al.
J Clin Invest
. 2023 Jan;
133(1).
PMID: 36594467
Accumulation of activated immune cells results in nonspecific hepatocyte killing in chronic hepatitis B (CHB), leading to fibrosis and cirrhosis. This study aims to understand the underlying mechanisms in humans...